Document 0013
 DOCN  M9550013
 TI    Pathology and pathophysiology of primary pulmonary hypertension.
 DT    9505
 AU    Rubin LJ; Department of Medicine, University of Maryland School of;
       Medicine, Baltimore.
 SO    Am J Cardiol. 1995 Jan 19;75(3):51A-54A. Unique Identifier : AIDSLINE
       MED/95142027
 AB    Primary pulmonary hypertension (PPH) is at present little understood. It
       is characterized by extensive remodeling of the pulmonary vasculature,
       with consequent deleterious hypertrophic changes in the right ventricle.
       Median survival is 2.6 years, although this varies with the severity of
       right heart failure. Although PPH can occur at any age and in either
       sex, it primarily affects young to middle-aged women. A genetic
       predisposition appears to be a component of this disease, triggered by
       presentation of a stimulus (e.g., drugs or HIV infection). Symptomatic
       presentation includes exertional dyspnea, chest pain, and syncope. At
       present, therapy consists principally of anticoagulation, calcium
       antagonists, nitric oxide inhalation, or continuous intravenous
       prostacyclin.
 DE    Human  Hypertension, Pulmonary/*PATHOLOGY/*PHYSIOPATHOLOGY  Support,
       U.S. Gov't, P.H.S.  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).